Stockscreener 앱 받기
0.6259
1.65%
-0.0105
시간 외 거래:
.61
-0.0159
-2.54%
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com
Nektar upgraded at Jefferies ahead of mid-stage readout for eczema drug - MSN
Nektar Therapeutics (NKTR) Shares Surge on Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq
Nektar Therapeutics (NKTR) Gains After Jefferies Upgrade - GuruFocus
Jefferies Upgrades Nektar Therapeutics (NKTR) - MSN
Sector Update: Health Care - TradingView
Jefferies Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance
Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance
Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha
Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga
Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - MarketScreener
Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India
Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider
IL-2 ADding contenders in eczema strategy - BioWorld MedTech
Nektar Therapeutics stock hits 52-week low at $0.44 By Investing.com - Investing.com Canada
Nektar Therapeutics stock hits 52-week low at $0.44 - Investing.com
Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding - simplywall.st
Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates - Dermatology Times
Nektar Therapeutics announces $75 million equity distribution - Investing.com Australia
Nektar Therapeutics announces $75 million equity distribution By Investing.com - Investing.com South Africa
Nektar TherapeuticsEnters Equity Distribution Agreement Up To $75 MillionSEC Filing - Marketscreener.com
Nektar Therapeutics (NKTR) Files $300M Mixed Securities Shelf Of - GuruFocus
Nektar Therapeutics Files For Mixed Shelf Offering Of Up To $300 MillionSEC Filing - MarketScreener
Nektar Therapeutics (NKTR) Files $300M Mixed Shelf - StreetInsider
IL-2s gain ground as US market heads for $4 billion by 2034 - The Pharma Letter
The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight - Yahoo Finance
Nektar at H.C. Wainwright Conference: Strategic Updates on Respegg Trials - Investing.com
Petrelintide up front shatters biotech deal record - biocentury.com
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil - Insider Monkey
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Lelezard
Nektar Therapeutics to Present Autoimmune Disease Updates at HC Wainwright Conference | NKTR Stock News - Stock Titan
Oppenheimer Upgrades Nektar Therapeutics (BMV:NKTR) - Nasdaq
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up - MSN
Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout - MSN
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript - MSN
Oppenheimer Upgrades Nektar Therapeutics (NKTR) - Nasdaq
NEKTAR THERAPEUTICS SEC 10-K Report - TradingView
Nektar Therapeutics Shares Rise After Upgrade From Oppenheimer -March 14, 2025 at 02:54 pm EDT - Marketscreener.com
Oppenheimer Upgrades Nektar Therapeutics (LSE:0UNL) - Nasdaq
Nektar stock upgraded at Oppenheimer (NKTR:NASDAQ) - Seeking Alpha
Oppenheimer Upgrades Nektar Therapeutics (NKTR) to Outperform - StreetInsider.com
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised) - Yahoo Finance
Oppenheimer Upgrades Nektar Therapeutics to Outperform From Market Perform, Price Target is $6 - Marketscreener.com
Nektar Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Oppenheimer raises NKTR stock to Outperform, sets $6 price target - Investing.com
Nektar Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks
BTIG keeps Nektar stock Neutral with $4.00 target By Investing.com - Investing.com Australia
Promising Pipeline and Strategic Positioning: Julian Harrison’s Buy Rating on Nektar Therapeutics - TipRanks
Nektar Therapeutics: Poised for Growth with Promising Rezpeg Study and Market Potential - TipRanks
Assessing Nektar Therapeutics: Insights From 4 Financial Analysts - Benzinga
0.15%
4.32%
자본화:
|
볼륨(24시간):